Stoke Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

STOK$27.71+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated balance sheets

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$191,442	$113,556
Marketable securities	9,952	116,039
Prepaid expenses	11,320	10,932
Other current assets	2,561	2,955
Interest receivable	64	588
Total current assets	$215,339	$244,070
Restricted cash	569	569
Operating lease right-of-use assets	6,611	4,753
Property and equipment, net	5,823	6,675
Total assets	$228,342	$256,067
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$1,695	$766
Accrued and other current liabilities	13,815	15,748
Deferred revenue - current portion	15,309	14,880
Total current liabilities	$30,819	$31,394
Deferred revenue - net of current portion	33,074	36,856
Other long term liabilities	4,884	2,968
Total long term liabilities	$37,958	$39,824
Total liabilities	$68,777	$71,218
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 45,918,233 and 39,439,575 shares issued and outstanding as of December 31, 2023 and 2022, respectively	5	4
Additional paid-in capital	561,433	483,170
Accumulated other comprehensive loss	(24)	(1,175)
Accumulated deficit	(401,849)	(297,150)
Total stockholders’ equity	$159,565	$184,849
Total liabilities and stockholders’ equity	$228,342	$256,067

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.